CDK12抑制通过抑制PI3K/AKT增强HER2阳性乳腺癌对HER2酪氨酸激酶抑制剂的敏感性
该研究通过CRISPR/Cas9文库筛选发现CDK12与HER2高频共扩增,抑制CDK12可增敏或再增敏HER2阳性乳腺癌对抗HER2 TKI拉帕替尼,机制涉及减弱PI3K/AKT信号。临床数据显示CDK12扩增患者抗HER2治疗反应更差、PFS更短。
要点
- CDK12与HER2高频共扩增,抑制CDK12可增敏或再增敏HER2阳性乳腺癌对拉帕替尼的敏感性。
- CDK12抑制通过减弱PI3K/AKT信号及p-AKT激活发挥作用。
- CDK12扩增患者抗HER2治疗PFS显著缩短(4.3 vs 6.9个月,HR=2.26,P=0.0028)。
核心结论
- HER2/CDK12双重抑制可通过增敏或再增敏肿瘤对抗HER2 TKI治疗,显著改善HER2阳性乳腺癌患者结局。
研究设计与样本
- 基于TCGA数据挖掘,采用CRISPR/Cas9敲除技术进行panel文库筛选,并在临床前模型和乳腺癌高通量测序数据集中验证候选靶点。
主要发现
- CDK12与HER2高频共扩增,抑制CDK12可增敏或再增敏HER2阳性乳腺癌对抗HER2 TKI拉帕替尼,证据来自患者来源类器官体外实验及细胞来源异种移植或患者来源异种移植体内实验。
- 抑制CDK12减弱PI3K/AKT信号,联合CDK12抑制对拉帕替尼诱导的p-AKT激活产生额外抑制。
- CDK12扩增的HER2阳性乳腺癌患者对抗HER2治疗反应更不敏感,中位PFS为4.3个月 versus 6.9个月,HR=2.26(95%CI=1.32-3.86),P=0.0028。
临床怎么用
- 对于HER2阳性乳腺癌,检测CDK12扩增可能有助于识别抗HER2 TKI治疗反应不佳的患者。
- CDK12抑制联合抗HER2 TKI可能成为增敏或再增敏的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alhtough anti-HER2 tyrosine kinase inhibitors (TKIs) have radically prolonged survival and improved prognosis in HER2-positive breast cancer patients, resistance to these therapies is a constant obstacle leading to TKIs treatment failure and tumour progression. METHODS: To develop new strategies to enhance TKIs efficiency by combining synergistic gene targets, we performed panel library screening using the CRISPR/Cas9 knockout technique based on data mining across TCGA data sets and verified the candidate target in preclinical models and breast cancer high-throughput sequencing data sets. RESULTS: We identified that CDK12, co-amplified with HER2 in a high frequency, is powerful to sensitise or resensitise HER2-positive breast cancer to anti-HER2 TKIs lapatinib, evidenced by patient-derived organoids in vitro and cell-derived xenograft or patient-derived xenograft in vivo. Exploring mechanisms, we found that inhibition of CDK12 attenuated PI3K/AKT signal, which usually serves as an oncogenic driver and is reactivated when HER2-positive breast cancers develop resistance to lapatinib. Combining CDK12 inhibition exerted additional suppression on p-AKT activation induced by anti-HER2 TKIs lapatinib treatment. Clinically, via DNA sequencing data for tumour tissue and peripheral blood ctDNA, we found that HER2-positive breast cancer patients with CDK12 amplification responded more insensitively to anti-HER2 treatment than those without accompanying CDK12 amplification by harbouring a markedly shortened progression-free survival (PFS) (median PFS: 4.3 months versus 6.9 months; hazards ratio [HR] = 2.26 [95% confidence interval [CI] = 1.32-3.86]; P = 0.0028). CONCLUSIONS: Dual inhibition of HER2/CDK12 will prominently benefit the outcomes of patients with HER2-positive breast cancer by sensitising or resensitising the tumours to anti-HER2 TKIs treatment.
引用
- Li H, Wang J, Yi Z, et al. CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT. Eur J Cancer. 2021. PMID: 33429148. doi:10.1016/j.ejca.2020.11.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。